Findings showed MELT-300 was statistically superior to both sublingual midazolam and placebo for providing successful procedural sedation. Topline results were announced from a phase 3 trial ...
Objectives: Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures. To overcome some of ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first ...
Evidence supports the use of intravenous (IV) ketamine for acute pain in a variety of contexts, including as a stand-alone treatment, as an adjunct to opioids, and, to a lesser extent, as an ...
Celebrities like Matthew Perry, Chrissy Teigen and others have been open about using ketamine infusion therapy to help treat mental health conditions. According to the United States Drug Enforcement ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — At the American Society of Cataract and Refractive Surgery meeting, Maggie Jeffries, MD, discusses a ...
Harrow has completed its deal to acquire Melt Pharmaceuticals, according to a company press release. Harrow announced its ...
NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...
Toronto, Ontario--(Newsfile Corp. - August 27, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the dosing of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback